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Abstract
Increased vascular permeability is an inciting event in many vascular complications including diabetic retinopathy. We have
previously reported that pigment epithelium-derived factor (PEDF) is able to inhibit vascular endothelial growth factor
(VEGF)-induced angiogenesis through a novel c-secretase-dependent pathway. In this study, we asked whether inhibition of
VEGF-induced permeability by PEDF is also c-secretase-mediated and to dissect the potential mechanisms involved.
Vascular permeability was assessed in vitro by measuring transendothelial resistance and paracellular permeability to
dextran and in vivo by following leakage of intravenous FITC-labelled albumin into the retina in the presence or absence of
VEGF and PEDF in varying combinations. Experiments were undertaken in the presence or absence of a c-secretase
inhibitor. To assess junctional integrity immunohistochemistry for the adherens junction (AJ) proteins, VE-cadherin and b-
catenin, and the tight junction (TJ) protein, claudin-5 was undertaken using cultured cells and flat mount retinas. Protein
expression and the association between AJ proteins, VEGF receptors (VEGFRs) and c-secretase constituents were
determined by immunoprecipitation and Western Blot analysis. In selected experiments the effect of hypoxia on junctional
integrity was also assessed. PEDF inhibition of VEGF-induced permeability, both in cultured microvascular endothelial cell
monolayers and in vivo in the mouse retinal vasculature, is mediated by c-secretase. PEDF acted by a) preventing
dissociation of AJ and TJ proteins and b) regulating both the association of VEGF receptors with AJ proteins and the
subsequent phosphorylation of the AJ proteins, VE-cadherin and b-catenin. Association of c-secretase with AJ proteins
appears to be critical in the regulation of vascular permeability. Although hypoxia increased VEGFR expression there was a
significant dissociation of VEGFR from AJ proteins. In conclusion, PEDF regulates VEGF-induced vascular permeability via a
novel c-secretase dependent pathway and targeting downstream effectors of PEDF action may represent a promising
therapeutic strategy for preventing or ameliorating increased vascular permeability.
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Introduction
The vascular endothelium regulates fluid and solute exchange
between the blood and interstitial space [1,2]. Increased vascular
permeability and vascular leakage by paracellular routes are usually
pathological and involved in conditions as diverse as cancer,
ischemic heartdisease,asthma,subcutaneous edema,inflammation,
wound healing and diabetic microvascular complications [3,4,5].
Furthermore, diabetic macular edema, which involves the break-
down of the blood–retinal barrier, also occurs and is responsible for
a major part of vision loss, particularly in Type 2 diabetes [6].
Paracellular permeability is mediated by the co-ordinated opening
and closing of endothelial cell-cell junctions [7,8]. These trans-
membrane complexes occur as tight junctions (TJs) and adherens
junctions (AJs) of which the latter, unlike epithelial cells,
predominate in endothelial cells [2,8]. The blood barrier requires
the adhesive properties of VE-cadherin and claudin-5 which arekey
components of the AJs and TJs respectively. The loss of AJ and TJ
integrity between endothelial cells leads to increased solute flux
[9,10]. Moreover, unlike epithelial cells, AJs and TJs are
intermingled in microvascular endothelial cells to form a complex
zonular system and adherens junctions are reported to regulate the
organization and stability of tight junctions [7,8].
Vascular endothelial growth factor (VEGF), originally termed
vascular permeability factor, is a key factor in the pathogenesis of
vascular complications including increased retinal vascular
permeability which is a hall mark of early diabetic retinopathy
[4,11]. In animal studies, intravitreal injection of VEGF results in
a rapid and sustained increase in vascular permeability in the
retina [12,13,14]. Furthermore, a variety of VEGF-blocking
strategies have confirmed the critical role of VEGF in the
permeability response of diabetic animal models [14,15,16,17] and
have shown a reduction in vascular permeability in patients with
diabetic macular edema [18,19,20,21]. Studies of the mechanisms
by which VEGF induces increases in vascular permeability
indicate that multiple pathways are involved [4]. The VEGF
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the most dominant in angiogenesis. VEGFA interacts with VEGF
receptor (VEGFR) 1 and 2 on vascular endothelial cells [22,23].
VEGFR2 signals via a strong tyrosine kinase signal which is able to
regulate endothelial function and survival via a number of
different signalling pathways [23]. By contrast, VEGFR1 has a
higher affinity for VEGF than VEGFR2 but only has weak kinase
activity. A growing body of evidence supports that VEGFR1 is a
potent regulator of VEGFR2 action [24,25]. Interestingly,
VEGFR2 is closely associated with VE-cadherin in AJs and has
been implicated in phosphorylation of proteins in the AJ complex
[26,27]. However, the role of VEGFR1 in the regulation of
endothelial junction integrity has received little attention.
Pigment epithelium-derived factor (PEDF) is a 50-kDa non-
inhibitory member of the serine protease inhibitor (Serpin) gene
family, and a potent antiangiogenic factor [28,29]. PEDF is secreted
by many retinal cells including the Mu ¨ller cells, vascular endothelial
cells, pericytes and retinal pigment epithelial cells and has been
reported toinhibitneovascularizationinanimalmodelsfordiabetes,
prevent the accumulation of advanced glycation endproducts,
reduce oxidative damage and reduce inflammation [30,31,32,33,
34]. Furthermore, vitreous levels of PEDF are significantly reduced
in diabetic macular edema [35,36]. Numerous studies have
demonstrated that PEDF inhibits VEGF- and stress-induced
vascular permeability both in vitro and in vivo [34,37,38,39,
40,41,42] but the mechanisms are poorly understood and no
definitive receptor has been identified for PEDF. To date, only two
binding partners have been identified for PEDF: a lipase-linked
membrane protein and a laminin receptor [29,43]. We have
previously reported that PEDF a) is down regulated in the diabetic
retina and tumors [44,45], b) inhibits growth factor-induced
angiogenesis in microvascular endothelial cells, c) regulates the
intracellular translocation of both intact and cleaved VEGFR1 and
c) blocks VEGF-induced phosphorylation of VEGFR-1 [24,46,47].
These events were dependent on c-secretase which is a complex
composed of four different integral proteins (presenilin, nicastrin,
Aph-1 and Pen-2) [46]. The most studied components of the c-
secretase complex are presenilin, which is an integral enzyme in the
transmembrane cleavage of substrates and nicastrin that is
purported to be essential for substrate recognition [46].
In this study we show that PEDF blocks VEGF-induced
vascular permeability by preventing dissociation of endothelial
AJs and TJs via a c-secretase-dependent mechanism. We further
demonstrate that PEDF regulates both the association of VEGF
receptors with AJ proteins and phosphorylation of the AJ proteins,
VE-cadherin and b-catenin. The association of c-secretase with AJ
proteins appears to be critical in the regulation of vascular
permeability. Finally, we show that hypoxia, which is a feature of
pathological angiogenesis, both upregulates VEGFR expression
and increases dissociation of VEGFRs from AJ proteins. This
represents a novel c-secretase-dependent pathway that regulates
vascular permeability.
Results
PEDF blocks VEGF-induced vascular permeability by
preventing dissociation of endothelial AJs and TJs via a
c-secretase-dependent mechanism
Addition of VEGF-A to cultured retinal microvascular endo-
thelial cells caused a significant 62% decrease in TER and 130%
increase in the transendothelial flux of flourescent dextran which
was sustained over a 24 hour period compared to untreated
control, cells treated with PBS alone, PEDF alone or c-secretase
inhibitor alone (Figs. 1a, b). However, PEDF significantly reduced
VEGF-induced permeability and this was dependent on time of
application. Cells treated with PEDF in combination with VEGF
at time 0 showed a significant ,50% decrease in VEGF-induced
permeability (Figs. 1a, b). However, this was not as great as that
observed when PEDF was applied 6 hours following VEGF.
Addition of PEDF post VEGF treatment resulted in complete
reversal of VEGF-induced permeability by 24 hours compared to
cells treated with VEGF alone. Higher concentrations of PEDF
did not further decrease VEGF-induced permeability (data not
shown) [24]. In all cases, c-secretase (which we have previously
shown inhibits PEDF signaling [24]) blocked the inhibitory effect
of PEDF on VEGF-induced permeability (Fig. 1c, 1d).
Immunohistochemistry demonstrated lateral membrane locali-
zation of VE-cadherin and claudin-5 in endothelial cell monolay-
ers and this was unaffected by addition of PEDF alone (Fig. 2) or
c-secretase inhibitor alone. The vehicle control remained identical
to VE-cadherin and Claudin-5 staining at time 0 throughout the
time course of the experiment. However, VEGF alone led to a
rapid disassociation of the cell-cell contacts and a major loss of
staining for VE-cadherin at the junctional complexes within
15 minutes and reduced staining for claudin 5 observed at 1 and
12 hours post treatment (Fig. 2). Addition of PEDF in combination
with VEGF (data not shown), or PEDF 6 hours post VEGF
treatment, prevented the VEGF-induced dissociation of lateral
junctional complexes (Fig. 3). However, c-secretase inhibition,
blocked the inhibitory effect of PEDF on VEGF-induced
junctional changes. b-catenin, which is associated with the
integrity of VE-cadherin in adherens junction [8], was dissociated
by VEGF and translocated to both the cytosolic and nuclear
compartments and this VEGF-induced dissociation was prevented
by PEDF (Fig. 3). Inhibition of c-secretase prevented the PEDF-
induced effect on VEGF dissociation of b-catenin.
To confirm that the ability of PEDF to inhibit VEGF-induced
permeability was not limited to cell culture, we repeated these
studies in mice. Intravitreal injection of VEGF in C57BL/6 mice
resulted in significant intraretinal leakage of systemically intro-
duced fluorescent albumin (Fig. 4). However, intravitreal injection
of PEDF either together with VEGF or 6 hr following VEGF
resulted in significant inhibition of VEGF-induced fluorescent
albumin leakage into the retina and this was greatest when PEDF
was injected 6 hours following VEGF (Fig. 4a). c-Secretase
inhibition blocked the inhibitory effect of PEDF on VEGF-
induced permeability (Fig. 4a). Confocal microscopy of flat mount
retinal preparations showed intraretinal fluorescent albumin in
greater than 90% of the retina in VEGF treated animals,
confirming increased vascular leakage compared to vehicle only
controls, PEDF alone or c-secretase inhibitor alone (Fig. 4b). By
marked contrast, minimal vascular leakage of fluorescent albumin
was observed in animals receiving PEDF and VEGF and in all
cases, c-secretase inhibition blocked the inhibitory effect of PEDF
on VEGF-induced permeability (Fig. 4b).
Using immunohistochemistry we stained for either VE-cadherin
or claudin 5 to assess the spatial relationship between AJ and TJ
protein expression and changes in paracellular vascular perme-
ability (Fig. 5). A typical staining for an intact vasculature will show
clearly demarcated lateral membranes of microvascular endothe-
lial cells. This was observed for both VE-cadherin and claudin-5 in
mouse eyes without injection or with intravitreal injection of the
PBS vehicle (Fig. 5a). Localization and integrity of junctional
complexes were not changed by exposure to PEDF alone or
c-secretase inhibitor alone over a 48 hour period. However,
intravitreal injection of VEGF resulted in an almost complete loss
of staining of the junctional network for greater than 90% of the
retinal vessels indicative of loss of junctional complexes and this
PEDF and c-Secretase Control Vascular Permeability
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retina (Fig. 5). By contrast, eyes which had received PEDF
simultaneously or 6 hrs after VEGF-induced vascular permeability
exhibited a pattern of VE-cadherin and claudin 5 staining similar
to that seen for controls in greater than 75% of the retina although
a few areas remained in which junctional complexes seemed to be
less well formed. The beneficial effect of PEDF on VEGF-induced
permeability was blocked by inhibition of c-secretase (Fig. 5).
PEDF regulates the association of VEGF receptors with AJ
proteins
Immunoprecipitation and Western blot demonstrated a strong,
but dynamic, association between VE cadherin, b-catenin and full
length VEGFRs 1 and 2 (Fig. 6). In the untreated cells, VEGFR1
demonstrated stronger association with VE-cadherin and b-
catenin than VEGFR2. PEDF alone did not affect this association.
However, a decreased VEGFR-1 association with VE-cadherin
Figure 1. PEDF blocks microvascular endothelial permeability via a c-secretase dependent mechanism. (a) Temporal changes in
transendothelial resistance across a microvascular endothelial monolayer grown on a Transwell insert treated with vehicle (unstimulated), VEGFA
alone, PEDF alone, simultaneous VEGFA+PEDF, PEDF 6 hours post VEGF (n=4 independent experiments). VEGFA and PEDF were used at 100 ng/ml.
(b) Paracellular macromolecular permeability to 40 kDa Dextran-FITC using the conditions described in (A) (n=4). In the case of PEDF 6 hours post
VEGF, Transwell inserts were transferred to new wells containing basal medium without fluorescent dextran. (c) and (d) The effect of c-secretase
inhibitor (c-SI) on PEDF reduction of VEGF-induced endothelial permeability; (c) TER, (d) paracellular flux. c-secretase inhibitors were used at 1 nM
and data is shown for L685485. Data are represented as means (n=4) 6 SEM.
doi:10.1371/journal.pone.0021164.g001
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the association of VEGFR-2 with VE-cadherin/b-catenin re-
mained unchanged, thus reducing the VEGFR-1:VEGFR-2 ratio.
By 6 hr, sustained presence of VEGF further reduced VEGFR-1
association with VE-cadherin/b-catenin but increased VEGFR-2
which led to a further reduction in the VEGFR-1:VEGFR-2 ratio.
By 24r, VEGF treatment not only caused a dissociation of the VE-
cadherin/b-catenin complex, but also an almost complete loss of
both VEGFR-1 and VEGFR-2 association with VE-cadherin or
b-catenin. Taken together, these data suggest that the ratio of
VEGFR1:VEGFR2 may be important in the integrity of AJs.
VEGF-induced VEGFR/VE-cadherin/b-catenin dissociation
could be blocked by adding PEDF and this could be reversed by
c-secretase inhibition (Fig. 6).
PEDF regulates VE-cadherin phosphorylation
Since many studies have implicated tyrosine phosphorylation of
VE-cadherin in modulation of endothelial permeability we
investigated the effect of PEDF on VE-cadherin phosphorylation.
As shown in Fig. 7a, VEGF-induced a rapid increase in tyrosine
phosphorylation of VE-cadherin in the membrane fraction, which
could be prevented by PEDF. A recent site directed mutagenesis
study showed that mutation of pY658 or pY731 in VE-cadherin
attenuated VEGF-induced permeability, suggesting that the
regulation of endothelium permeability by VEGF requires the
phosphorylation of VE-cadherin at tyrosine 658 and 731 [48]. As
expected, VEGF induced a significant increase in the levels of
pY658 and pY731 in the protein samples of the membrane
factions (Fig. 7b). However, cytosolic VE-cadherin was not
phosphorylated at pY658 and pY731 even though immunopre-
citation with PY20 and subsequent Western blot for VE-cadherin
showed strong tyrosine phosphorylation of VE-cadherin within
cytosolic fractions (data not shown). Furthermore, PEDF inhibited
the effects of VEGF and this was reversed by addition of a c-
secretase inhibitor (Fig. 7b). This was confirmed by Western blot
using antibodies against VE-cadherin pY658 and pY731. The
total tyrosine phosphorylation of membrane-associated b-catenin
showed a very similar pattern to that of VE-cadherin upon
treatment with VEGF, PEDF and c-secretase inhibitor (Fig. 7c).
Presenilin-1 and nicastrin associate with VE-cadherin and
regulate vascular permeability
We confirmed a relationship between c-secretase and VE-
cadherin using both Western blot and siRNA knockdown (Fig. 7
d,e). The major c-secretase components, presenilin-1 (PS1) and
nicastrin (NCT), showed a strong association with VE-cadherin
and this was significantly decreased following exposure of cells to
VEGF (Fig. 7d). PEDF prevented VEGF-induced dissociation and
interestingly PEDF was able to significantly increase these
associations even without VEGF present. The effects of PEDF
were prevented by a c-secretase inhibitor. Furthermore, siRNA
knockdown of PS1 and NTC was able to reduce the inhibitory
effect of PEDF on VEGF-induced permeability of endothelial cells
(Fig. 7e).
Hypoxia increases vascular permeability
Since angiogenesis normally occurs in a hypoxic environment
we next examined to what extent junctional integrity was
dependent on the local oxygen environment. We chose three
oxygen environments based on our previous studies [49]; retinal
hypoxia, inner retinal normoxia and standard incubator condi-
tions. Under hypoxic conditions, vascular permeability demon-
strated a gradual but significant (p,0.05) decrease in TER and
increase in transendothelial flux in the absence of exogenous
Figure 2. The temporal response of AJs and TJs to VEGF or VEGF plus PEDF. Representative pictures of confluent cultures of microvascular
endothelial cells treated with VEGFA alone or VEGFA followed by PEDF 6 hours later triple stained for VE-cadherin (red), claudin-5 (green) and nuclei
(DAPI) and assessed at different times over 24 hours using confocal microscopy. VEGFA and PEDF were used at 100 ng/ml. Scale bar=100 mm.
doi:10.1371/journal.pone.0021164.g002
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normoxia or standard incubator conditions (Fig. 8, Fig. 1a,b).
VEGF-induced permeability was significantly increased under
hypoxia compared to the other oxygen environments. Interest-
ingly, PEDF had a greater inhibitory effect on VEGF-induced
permeability under hypoxia than either normoxia or standard
incubator conditions and in all cases this was completely inhibited
by blocking c-secretase (Fig. 8, Fig. 1).
Figure 3. PEDF prevents VEGF-induced dissociation of endothelial AJs and TJs. Representative immunofluorescent images of confluent
cultures of microvascular endothelial cells treated with vehicle (unstimulated), VEGFA alone, PEDF alone, simultaneous VEGFA+PEDF, PEDF 6 hours
post VEGF and PEDF 6 hours post VEGF+c-secretase inhibitor (c-SI) (n=4 independent experiments). VEGFA and PEDF were used at 100 ng/ml and c-
secretase inhibitor at 1 nM. (a) Cultures were triple stained for VE-cadherin (red), claudin-5 (green) and nuclei (DAPI, blue) and assessed at different
times over 24 hours using confocal microscopy. Merged images are shown with colocalization of VE-cadherin and claudin-5 appearing as yellow. (b)
The effect of PEDF on b-catenin using the conditions described in (A) (n=4). Scale bar=100 mm.
doi:10.1371/journal.pone.0021164.g003
PEDF and c-Secretase Control Vascular Permeability
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c-secretase along with VEGFR dissociation from AJ
proteins
It is well recognized that hypoxic conditions have profound
effects on the endothelial junctions [50,51]. Western blot
demonstrated that hypoxia induced a time-dependent increase in
VEGFR-1, VEGFR-2, presenilin-1 and nicastrin but had no
significant effect on the expression of VE-cadherin and b-catenin
(Fig. 9a) compared to normoxic and incubator conditions. To
further characterize the effect of hypoxia we used immunoprecip-
itation and Western Blot to determine the association between
VEGF receptors and AJ proteins. Hypoxia caused a significant
decrease in the association of VE cadherin with b-catenin and the
VE-cadherin complex with VEGFR-1 and VEGFR-2 compared
to normoxia (Fig. 9b).
Discussion
Tightly regulated vascular permeability plays a major role in
vascular homeostasis. However, increased vascular permeability is
a hallmark of numerous ocular conditions including diabetic
retinopathy [4,52,53]. Increased leakiness of retinal vessels is
apparent in both early, non-proliferative diabetic retinopathy as
well as late stage, proliferative diabetic retinopathy with ensuing
macular edema. Breakdown of the blood retinal barrier during
diabetes has a strong association with increased VEGF levels and
numerous VEGF-blocking strategies have been shown to reduce
retinal vascular permeability [4]. PEDF, by contrast, functions as a
potent anti-vasopermeability factor and acts primarily by blocking
the biological actions of VEGF [39,40]. However, since PEDF
levels are reduced and VEGF levels increased in diabetic
retinopathy [4,44] this favors increased vascular permeability.
Thus our observation that PEDF blocks VEGF-induced vascular
permeability in vitro and in vivo is in keeping with the published
literature [37,38,40,41,54]. However, PEDF maximally reduced
VEGF-induced permeability if applied 6 hours following VEGF
rather than PEDF given simultaneously with VEGF. Certainly this
effect is not specific to PEDF as we have previously reported a
more profound effect for placenta growth factor-1 (PlGF-1) on
VEGF-induced permeability [55]. We believe that the cells need
to be primed with VEGF before they can respond fully to PEDF
inhibition and utilize VE-cadherin to stabilize the endothelial
junctions. Furthermore, there is increasing evidence that growth
factor levels, including VEGF [56], fluctuate within microenvi-
ronments and thus the order of exposure may be a critical factor
that determines cellular response.
Tight junctions (TJs) and adherens junctions (AJs) play a major
role in the control of vascular permeability and this barrier
function requires the expression and organization of VE-cadherin
and claudin-5, which are essential components of adherens
junctions (AJs) and tight junctions (TJs) respectively [9,10] in both
the blood-brain and blood-retinal barriers. Cells require AJ
formation to build TJs [57,58] and recent reports indicate that
co-ordinated disruption of VE-cadherin intracellular interactions
culminates in the restructuring of both AJs and TJs and the
subsequent opening of endothelial cell-cell junctions [9,10,59].
Figure 4. PEDF blocks VEGF-induced retinal vascular permeability in mice. C57BL/6 mice received intravitreal injections of vehicle
(unstimulated), VEGFA alone, PEDF alone, simultaneous VEGFA+PEDF, PEDF 6 hours post VEGF and PEDF 6 hours post VEGF+c-secretase inhibitor
(cSI) (n=18 animals per treatment). Test compounds (1 ml per eye were given at the following concentrations, VEGF 80 ng/ml; PEDF (80 ng/ml);
L685485 24 ng/ml; DAPT 16 ng/ml. 46 hours post the first injection mice received tail vein injections of FITC-labeled albumin. Uninjected animals acted
as the baseline control. (a) 46 hours post the first injection mice received tail vein injections of FITC-labeled albumin and retinas were taken for
analysis 2 hours later (n=10–20 per group). Leakage of systemic FITC-labeled albumin into the retina was assessed by measuring total fluorescence
in homogenized retina using a fluorescence plate reader. Control is the baseline fluorescence in untreated animals. Data are represented as means 6
SEM. (b) Representative confocal microscopy showing dilated vessels and leakage of FITC-labeled albumin in the retinas of mice treated with vehicle
(unstimulated), VEGF, PEDF, PEDF 6 hours post VEGF and PEDF 6 hours post VEGF+c-secretase inhibitor (c-SI). Scale bar=50 mM.
doi:10.1371/journal.pone.0021164.g004
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PLoS ONE | www.plosone.org 6 June 2011 | Volume 6 | Issue 6 | e21164Figure 5. PEDF prevents VEGF-induced dissociation of endothelial AJs and TJs in the retinal vasculature of mice. (a) Representative
confocal images of retinal vessels in flat mount preparations from unstimulated and animals, treated as described in Figure 4, immunostained with
VE-cadherin or claudin-5 (red) and FITC-conjugated agglutinin (green) to visualize retinal vessels. Merged images are shown with colocalization of VE-
cadherin and claudin-5 appearing as yellow. Scale bar=50 mM. The lower panel (b) shows representative merged higher power images of retinal
vessels stained for VE-cadherin (i–iii) or claudin-5 (iv–vi) (red) and FITC-conjugated agglutinin (green). i, iv=unstimulated; ii, v=VEGF treatment; iii,
vi=PEDF 6 hr after VEGF. Scale bar=10 mM.
doi:10.1371/journal.pone.0021164.g005
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AJs within about 15 minutes while changes in tight junctions are
not observed until significantly later. PEDF acts to stabilize these
junctional complexes, and in the case of exposure to PEDF
following VEGF is able to rapidly reverse VEGF-induced
dissociation of junctional complexes which occurs in AJ’s prior
to TJ’s. This supports reports that co-ordinated disruption of VE-
cadherin intracellular interactions culminates in the restructuring
of both AJs and TJs and the subsequent opening of endothelial
cell-cell junctions [9,10,59].
AJs are a complex of vascular endothelial-cadherin (VE-
cadherin), a-catenin and b-catenin [1]. VE-cadherin is a trans-
membrane protein that plays a crucial role in the formation and
maintenance of AJs. b- and c-catenins can bind to cytoplasmic tail
of VE-cadherin and link it to a-catenin, which in turn binds to the
actin cytoskeleton [1,8]. Tyrosine phosphorylation of VE-cadherin
and other AJ proteins typically weaken cell-cell adhesions and
increase vascular permeability [8]. VEGF-induced a rapid
increase in tyrosine phosphorylation of VE-cadherin and that this
occurred primarily at tyrosine 658 and 731 as previously reported
[48]. PEDF blocked VEGF-induced total phosphorylation of
membrane VE-cadherin as well as phosphorylation at Y658 and
Y731. Tyrosine phosphorylation of membrane-associated b-
catenin showed a very similar pattern to that of VE-cadherin
upon treatment with VEGF and PEDF. Reports to date indicate
that PEDF may prevent VEGF-induced permeability by inhibiting
Src kinase activity [38], blocking VEGFR-2 activated phosphor-
ylation of the MAP kinase/b-catenin signaling pathway [41] and
Figure 6. PEDF maintains the association between AJ proteins and VEGF receptors in VEGF treated cells. Confluent retinal endothelial
cells were either unstimulated (1) treated with VEGF alone (2), PEDF alone (3), VEGF followed by PEDF 6 hours later without (4) and with (5)
c-secretase inhibitor for 24 hours. VEGFA and PEDF were used at 100 ng/ml and c-secretase inhibitor at 1 nM. Total cell lysates were split into four
equal portions and immunoprecipitated with anti-VE-cadherin, anti-b-catenin, anti-VEGFR1-C-terminus and anti-VEGFR2-C-terminus, and then
subsequent Western blot analyzed using these four antibodies, respectively. (a) A panel of representative Western blots. (b) Band intensities of
replicate experiments (n=4 independent experiments) were quantified as described in the Methods and regression analysis undertaken to assess the
association of these proteins.
doi:10.1371/journal.pone.0021164.g006
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PLoS ONE | www.plosone.org 8 June 2011 | Volume 6 | Issue 6 | e21164Figure 7. PEDF inhibits VEGF-induced phosphorylation of membrane-bound AJ proteins and promotes association of presenilin
and nicastrin with VE-cadherin. Confluent retinal endothelial cells were either unstimulated (1) treated with VEGF alone (2), PEDF alone (3), VEGF
followed by PEDF 6 hours later without (4) and with (5) c-secretase inhibitor over 24 hours. VEGFA and PEDF were used at 100 ng/ml and c-secretase
inhibitor at 1 nM. Cells were separated into membrane and cytosolic fractions followed by immunoprecipitation. (a) Total VE-cadherin levels were
determined by immunoprecipitation of the membrane fraction with anti-PY20 and Western blots for VE-cadherin. A panel of representative Western
blots is shown on left and band intensities of replicate experiments (n=4) on the right. (b) Western blot analysis to assess the effect of the different
treatments on tyrosine phosphorylation of VE-cadherin at sites Y658 and Y731 (n=4 independent experiments). (c) Total phosphorylation of b-
catenin was assessed by immunoprecipitation of the membrane fraction with anti-PY20 and Western blots for b-catenin. (n=4) (d) The association of
presenilin-1 (PS1) and nicastrin (NTC) were confirmed by immunoprecipitation with anti-VE-cadherin, followed by Western blot analysis using anti-
presenilin-1 and nicastrin. (e) To further confirm a role for c-secretase in regulating vascular permeability presenilin-1 or nicastrin were knocked down
with by transfection with AAV 2 expressing PS1 and NTC siRNAs. Scrambled siRNA acted as a control. Paracellular macromolecular permeability to
40 kDa Dextran-FITC was determined in cells treated with VEGF, PEDF, VEGF+PEDF and compared to unstimulated control. Densitometry analyses in
(a),(c)and(d)areshownastherelative ratioofphosphorylatedpVE-cadherin,pb-catenin,presenilin-1 andnicastrin toheavyIgGchains. Densitometryin
b is shown as the relative ratio to a-tubulin. The data are mean 6 SEM. *p,0.05, **p,0.01 versus unstimulated group.
doi:10.1371/journal.pone.0021164.g007
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proteolytic degradation of VE-cadherin, alters the blood retinal
barrier [60]. Our study identifies a novel, c-secretase-dependent
pathway, by which PEDF can regulate vascular permeability via
translocation of VEGFRs. Both in vitro and in vivo inhibition of c-
secretase abrogated the beneficial effects of PEDF on VEGF-
induced vascular permeability. This is in keeping with our
previous observations that PEDF acts as a potent inhibitor of
VEGF-induced angiogenesis by a c-secretase-dependent translo-
cation of both full length VEGFR and a cleaved intracellular
domain of VEGFR-1 [24]. In this study we show a dynamic,
association between AJ proteins and full length VEGFR-1 and
VEGFR-2. Our data would indicate that the ratio of VEGFR1:-
VEGFR2 may be important in maintaining the integrity of AJs. In
untreated cells, VEGFR1 demonstrates stronger association with
AJs than VEGFR2 while, in contrast, within 1 hour of VEGF
treatment the ratio is reversed in favor of VEGFR2 association
with AJs. Following 24 hour treatment with VEGF there is no
association with AJ proteins, presumably because the AJs are fully
dissociated by this time. PEDF prevented the change in
VEGFR1:VEGFR-2 ratio and the dissociation of AJs, moreover,
this change in ratio was dependent on c-secretase activity.
VEGFR-2 is associated with VE-cadheren at AJs and VEGFR-2
may be responsible for the direct phosphorylation of AJ proteins
[8,61]. Furthermore, we have recently reported that neutralization
of VEGFR-2 significantly decreases VEGF-induced phosphoryla-
tion of VE-cadherin while neutralization of VEGFR-1 induced
phosphorylation of VE-cadherin [55]. This is in keeping with the
current concept that VEGFR-1 is a potent negative regulator of
VEGFR-2. However, it should be noted that not all retinal cells
may behave the same since PEDF appears to prevent VEGF-
mediated permeability in RPE cells by c-secretase-dependent
processing of VEGFR-2 [62].
Cells require AJ formation to build TJs [57,58] and co-
ordinated disruption of VE-cadherin intracellular interactions
culminates in the restructuring of both AJs and TJs [9,10,59].
Furthermore, VE-cadherin regulates both claudin-5 expression
and phosphorylation [9,59,63]. These observations are in keeping
with our findings that changes in TJ integrity proceed AJ changes
and that AJs re-associated before TJs. These key observations
would indicate that AJs may offer a better therapeutic target when
attempting to prevent or reverse increased retinal permeability and
intraretinal leakage.
The association between both presenilin-1 and nicastrin with
VE-cadherin is intriguing and could be responsible for either
processing of VEGFRs or AJ proteins. With respect to AJ proteins,
c-secretase cleavage of both N-cadherin or E-cadherin can lead to
disassembly of AJs and an intracellular signalling cascade [64,65].
However, our studies would indicate that this may not be the case
for endothelial cells since VEGF decreased c-secretase association
Figure 8. Hypoxia increases vascular permeability. Temporal changes in transendothelial resistance across a microvascular endothelial
monolayer grown on a Transwell insert treated with vehicle (unstimulated), VEGFA alone, PEDF alone, simultaneous VEGFA+PEDF, PEDF 6 hours post
VEGF and PEDF 6 hours post VEGF+c-secretase inhibitor (c-SI) under either (a) hypoxia or (b) retinal normoxia. (n=4 independent experiments).
VEGFA and PEDF were used at 100 ng/ml and c-secretase inhibitor at 1 nM. In the case of PEDF 6 hours post VEGF, Transwell inserts were transferred
to new wells containing basal medium without fluorescent dextran. Data are respresented as means6 SEM.
doi:10.1371/journal.pone.0021164.g008
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processing of VEGFRs as the critical positive regulator of AJ
stabilization.
Although tissue hypoxia is regarded as a major factor in the
pathogenesis of diabetic retinopathy there is little known about
how this can affect the integrity of AJs. In the absence of
exogenous growth factors vascular permeability gradually in-
creased under hypoxic conditions, presumably due to the increase
in angiogenic factors such as VEGF. Hypoxia caused a significant
decrease in the association of VE cadherin with b-catenin, and
VEGFRs further emphasizing that hypoxia facilitates increased
vascular permeability. Furthermore, hypoxia in untreated cells
induced a time-dependent upregulation of VEGFRs, presenilin-1
and nicastrin but not VE-cadherin and b-catenin compared to
normoxia. Interestingly, exogenous PEDF had a greater inhibitory
effect on VEGF-induced permeability under hypoxia than
normoxia. This is unlikely to be due to increased PEDF levels
since PEDF is downregulated under hypoxia.
Figure 9. Hypoxia increases the expression of VEGF receptors and c-secretase along with VEGFR dissociation from AJ proteins. (a)
Confluent retinal microvascular endothelial cells were exposed to hypoxia for up to 24 hours. Cell lysated were examined by Western blot for VEGFR1,
VEGFR2, presenilin-1 (PS-1), nicastrin (NCT), VE-cadherin and b-catenin. a-tubulin acted as the house keeping control. A representative Western blot is
shown together with densitometric analysis from three separate experiments. (b) Confluent retinal microvascular endothelial cells were maintained
under standard incubator conditions, retinal normoxia and hypoxia for 24 hours. Total cell lysates were split into four equal portions and
immunoprecipitated with anti-VE-cadherin, anti-b-catenin, anti-VEGFR1-C-terminus and anti-VEGFR2-C-terminus, and then subsequent Western blot
analyzed using these four antibodies, respectively. A panel of representative Western blots is shown. Band intensities of replicate experiments (n=4)
were quantified as described in the Methods and regression analysis undertaken to assess the association of these proteins.
doi:10.1371/journal.pone.0021164.g009
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induced vascular permeability via a novel c-secretase dependent
pathway, b) the ratio of VEGFR-1:VEGFR-2 is important in
determining the degree of vascular permeability and c) hypoxia
makes microvascular endothelial cells more susceptible to increased
vascular permeability. Our studies would suggest that targeting
downstream effectors of PEDF, such as VEGFR translocation and/
or processing or c-secretase activity may represent a promising
therapeutic strategy for the treatment of diabetic vascular com-
plications in the eye and other organs.
Materials and Methods
Materials
Recombinant VEGF165 was purchased from R&D systems
(R&D Systems, Minneapolis, MN, USA) and PEDF from
BioProducts MD (BioProducts MD, Middletown, MD, USA).
c-secretase inhibitors L685485 and DAPT were obtained from
Sigma (Sigma, St. Louis, MO, USA). Anti-VE-cadherin antibody
was obtained from Cell Signaling (Cell Signaling, Danvers, MA,
USA), while anti-VE-cadherin pY568 and 731 antibodies were
purchased from Invitrogen (Invitrogen, Carlsbad, CA). Both anti-
b-catenin and a-tubulin antibodies were from Abcam (Abcam,
Cambridge, MA, USA). Anti-presenilin 1 and nicastrin antibodies
were obtained from Santa Cruz (Santa Cruz Biotechnology, Santa
Cruz, CA, USA).
Cell culture
Bovine retinal microvascular endothelial cells were isolated as
previously described [24]. In brief, bovine retinas in ice cold
Eagle’s minimal essential medium (MEM) with HEPES were
homogenized and microvessels trapped on an 83 mm nylon mesh.
Vessels were transferred to a cocktail containing 500 mg/ml
collagenase, 200 mg/ml pronase and 200 mg/ml DNase at 37uC
for 20 min. The resultant vessel fragments were trapped on 53 mm
mesh, washed with MEM and centrifuged at 225 g for 10 min.
The pellet was resuspended in microvascular endothelial cell basal
medium (MCDB131) with growth supplement (Invitrogen, CA) at
37uC, 5% CO2 for 3 days. Purity was confirmed by Factor VIII
and VE cadherin staining. Cells were used between passage 1 and
3 and all experiments were undertaken under standard incubator
conditions unless otherwise stated. For permeability studies,
endothelial cells were maintained at confluence for 3–4 weeks to
allow establishment of junctional complexes and a transendothelial
resistance of .20 V.cm
2.
Growth factor treatment
Confluent endothelial cell cultures were rendered quiescent for
45 min in serum-free basal medium VEGF-A and PEDF (alone or
in combination) were added at 100 ng/ml based on our previous
studies [24] and in the sequences indicated in the text for different
time intervals. We extrapolated from this to select our choice of
doses for the in vivo studies. Experiments were undertaken in the
presence or absence of 1 nM c-secretase inhibitors L685485 or
DAPT (Sigma). Cells were analyzed at varying time periods as
described below.
Regulation of the oxygen environment
Three experimental oxygen environments were achieved using
oxygen controlled glove boxes attached via a central airlock with
O2,C O 2,N 2, temperature and humidity control (Coy Laboratory
Products Inc., Grass lake, MI): hypoxia, pO2=5 mmHg; normoxia
for the inner retina, pO2=40 mmHg; standard incubator condi-
tions, pO2=135 mmHg [49]. All media and solutions were pre-
equilibrated for 24 hours at the appropriate oxygen concentration
prior to the beginning of the experiment. Confluent retinal
microvascular endothelial cells in 6-well plates or on Transwell
inserts were exposed to growth factors as described above and
processed at different time points for TER and Western Blot
analysis as described below.
In vitro permeability measurements
Endothelial cells were maintained at confluence on porous
polyester membrane inserts (6.5 mm diameter, 0.4 mm pore size;
Transwell, Corning, Cambridge, MA) for up to four weeks prior to
experimentation. The upper and lower compartments contained
100 ml and 0.5 ml of media, respectively. Experimental treatments
with growth factors and/or c-secretase inhibitor as described
above were added to the upper compartment.
Transendothelial Resistance (TER) Measurement. TER
measurements were performed using an EVOM volt-ohmmeter
(World Precision Instruments, Sarasota, FL). At the indicated time
intervals, resistance readings (V) were obtained from each insert
and multiplied by the membrane area (V6cm
2) to obtain values of
TER. The resistance value of an empty culture insert (no cells) was
subtracted. Data were collected from triplicate inserts per
treatment in each of three separate experiments.
Paracellular permeability assay. The growth medium in
the upper chamber was replaced with 100 ml of growth medium
containing a 1 mg/ml FITC-dextran 20 or 40 and the cells
allowed to equilibrate at 37uC for 15 min. Twenty ml of stock
growth factors and/or c-secretase inhibitor were added to the
medium to achieve the concentrations and combinations as
described above. In the case of addition of PEDF 6 hours
following VEGF, Transwell inserts were transferred to new wells
containing basal medium without fluorescent dextran. A 50 ml
sample of medium was taken in triplicate from the lower chamber
at various times and placed in a 96-well cluster plates to measure
fluorescent intensity (excitation at 530 nm and emission at
590 nm). In all cases the volume of the basal chamber was
maintained at 500 ml by replacement of the 50 ml sample with
50 ml of fresh medium.
In vivo retinal permeability assay
All animal studies were performed under a protocol approved
by the Institutional Animal Care and Use Committee at the
University of Florida, (IACUC Study #201005197), and in
accordance with the ARVO Statement for the Use of Animals
in Ophthalmic and Vision Research. In vivo retinal vascular
permeability was assessed as previously described [55]. Eight-
week-old C57BL/6 mice were purchased from Jackson Labora-
tories (Bar Harbor, ME). Mice received the following intravitreal
injections (1 ml) with a 32-gauge needle into one eye: VEGF;
PEDF; VEGF plus PEDF together; 0.9% saline vehicle; VEGF
followed by PEDF 6 hours later; VEGF plus c-secretase inhibitor
(L685485 or DAPT); PEDF plus c-secretase inhibitor; VEGF plus
PEDF plus c-secretase inhibitor; VEGF followed by 0.9% saline
6 hours later. Based on previous titration studies (data not shown)
test compounds were given at the following concentration, VEGF
80 ng/ml; PEDF (80 ng/ml); L685485 24 ng/ml; DAPT 16 ng/ml.
46 hours post the first injection mice received tail vein injections of
FITC-labeled albumin (0.5 mg in 50 ml vehicle). The mice were
placed on heating pads to maintain normal body temperature.
After 2 hours the mice were treated in two ways: 1) For albumin
leakage measurements animals were killed and the eye that
received the intravitreal injection enucleated and the retinas
removed and placed in PBS. The retina were rinsed in buffer,
disrupted mechanically, cleared by centrifugation and the FITC-
PEDF and c-Secretase Control Vascular Permeability
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standard curve of FITC-albumin using a spectrofluorometer as
previously described [55]. 2) For histology and immunostaining
the mice were perfused with 4% paraformaldehyde by cardiac
puncture prior to enucleation of the eyes.
Immunocytochemistry
Cell cultures. Bovine retinal microvascular endothelial cells
were cultured on glass bottom microwell dishes (MatTek
Corporation, MA) coated with attachment factor. At confluence
cells were fixed with 4% paraformaldehyde plus 4% sucrose in
PBS and permeabilized with 0.1% Triton X-100. Non-specific
staining was blocked with 5% BSA in PBS for 30 min at room
temperature. The cells were then dual labelled with goat
polyclonal anti-VE-cadherin antibody (Santa Cruz) and rabbit
polyclonal anti-Claudin-5 ( Abcam, MA) all at 1:1000 in PBS
containing 5% BSA at 4uC overnight. The secondary antibodies
Alexa Fluor 549-labeled donkey anti-goat IgG (Invitrogen, CA) for
VE-cadherin and Alexa Fluor 488-labeled donkey anti-rabbit IgG
(Invitrogen, CA) for Claudin-5, all at 1:1000 in 5% BSA in PBS at
room temperature for 1 hour in the dark. Exclusion of the primary
antibody acted as the negative control. Staining was evaluated and
digital photomicrographs obtained using an Olympus IX81-DSU
Spinning Disk confocal microscope.
Retinal flat mounts. Retina from the mouse studies were
carefully removed from the eyecup, permeabilized with 0.2%
Triton X-100 and non-specific binding blocked by 10% normal
goat serum in PBS overnight at 4uC. The retinas were then
transferred to a solution of primary antibody and incubated for
24 hours at 4uC. The primary antibodies were rabbit anti-VE-
Cadherin (1:100, Cell Signaling Technology, Inc., Danvers, MA,
USA) and rabbit anti-Claudin-5 (1:3000, Abcam Inc., Cambridge,
MA, USA). The retinas were transferred to the secondary
antibody for 24 hours at 4uC after washing in PBS with 0.2%
Triton X-100. The secondary antibody was Cy3 conjugated goat
anti-rabbit IgG (1:250). To specifically label the vascular
endothelium, the retinas were then incubated 30 minutes at
room temperature in 1:500 FITC-conjugated agglutinin in
10 mM HEPES, 150 mM NaCl and 0.1% Tween 20. Exclusion
of the primary antibody acted as the negative control. Retinas
were flat mounted onto microscope slides and covered in aqueous
VectaShield mounting medium (Vector Laboratories, Inc.,
Burlingame, CA) for observation by confocal microscopy. Digital
confocal images were captured with an Olympus DSU-Olympus
IX81 confocal microscope (Olympus America, Inc., Center
Valley, PA, USA). Digital images from experimental and control
retinas with identical photomultiplier tube gain settings were
captured by using imaging software-SlideBook
4.2.. Maximum
projections generated from z-section stacks of confocal images
were processed identically in experimental and control retinas.
Immunoprecipitation and Western blotting
Different subcellular fractions (membrane and cytosolic) were
prepared from microvascular endothelial cells receiving the
different treatments using a Subcellular Protein Extraction Kit
according to the manufacturer’s instructions (Calbiochem, San
Diego, CA). Purity of fractions was confirmed by Western Blot
using antibodies against pan-cadherin (membrane); histone 1
(nuclear); pan-cytokeratin (cytoskeleton); calpain (cytosolic).
For immunoprecipitation, individual capture antibody (2 mg/ml)
was mixed with 250 mL of cell lysates for 1–2 h at 4uC. Protein A/G
plus Agarose was added (20 ml) and agitated overnight at 4uC.
Agarose beads were washed 3 times and resuspended in PBS. The
samples were boiled for 5 min and immunocomplexes were resolved
on SDS-polyacrylamide gels (7.5%–12%) and subjected to Western
blotting.
For Western blotting, 30 mg of cell lysate was electrophoresed
on 7.5%–12% SDS-polyacrylamide gels under reducing condi-
tions for VE-cadherin, b-catenin, VEGFR-1, and VEGFR-2,
presenilin-1, nicastrin, PY20 (polyclonal antibodies, Santa Cruz
Biotechnology), Claudin-5, VE-cadherin (pY658 and pY731)
(polyclonal antibodies, Abcam Inc.) After electrophoresis, proteins
were transferred onto nitrocellulose membranes (Bio-Rad) and
nonspecific binding sites were blocked with 10% non-fat dry milk
in PBS. Blots were probed with the above antibodies used at a
concentration of 0.1 mg/ml, followed by an HRP-conjugated
secondary antibody. The membranes were incubated with ECL
Plus Western blotting detection system (Amersham Biosciences,
Piscataway, NJ) and exposed to Biomax MR film (Sigma). Band
intensities were determined using NIH Image.
Protein association studies
To determine if there is association of b-catenin, VE-cadherin,
VEGFR-1 and VEGFR-2 during VEGF/PEDF/VEGF+PEDF-
induced signaling, the cells were treated with growth factors as
described above. Then 1 ml of cell lysate containing 500 mg/ml
protein for each treatment was divided into four equal portions.
The four portions were immunoprecipitated with either rabbit
anti- b-catenin, VE-cadherin, VEGFR-1 and VEGFR-2 antibod-
ies. For control, preimmune sera were used to replace the primary
antibodies. After Western blotting analysis with the same four
antibodies, the band intensity was determined by NIH Image and
regression analysis undertaken as previously described [47].
Statistics
All experiments were repeated at least three times. The TER
and paracellular permeability data at different time points were
assessed using a Student’s t test plus ANOVA for multiple
comparisons. The Mann-Whitney test was used to determine
statistical significance in the data of protein expression obtained
using Western blotting analysis. Results are expressed as mean6-
standard error of the mean. Statistical analysis was performed
using Prism 5 (GraphPad Software, La Jolla, CA) with p,0.05
considered statistically significant.
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